This Core Center of Excellence in Hematology (CCEH) is designed to overcome feasibility issues that limit the ability of individual investigators to apply state-of-the-art methods to isolate, characterize, manipulate and functionally analyze hematopoietic cells. This is achieved through services provided by the five biomedical research cores: B, large scale cell processing;C, clonal analysis;D,vector production;E. xenografting;and F, canine resources. The Administrative Core (Core A) provides managerial, scientific, and budgetary oversight for these core activities. In addition Core A is responsible for administrating the Pilot and Feasibility (P&F) studies program and the Enrichment Program. These two programs are supported by program income derived from charge back fees levied for core services. Management of program income is also under the purview of Core A. The Enrichment Program, under the direction of the Administrative Core, serves the hematology research community by sponsoring 3-6 outside speakers per year to present at the well-established Clinical Research Division Monday noon lecture series. This lecture series also provides CCEH members with an opportunity to formally present their research, which Is a requirement for appointments and promotions. Lectures are held every Monday at the FHCRC and usually attract between 50-75 people. Lectures are also made available through a live feed to the UW, Children's Hospital, Seattle Cancer Care Alliance, Seattle VA, University of British Columbia, and University of Victoria. The live feed allows audience participation at the remote sites. Faculty members attending these lectures will receive CME credits. In addition to the sponsored speaker program, the CCEH will co-sponsor a workshop on circulating microRNAs and DNAs, and their potential role In mediating cell to cell interactions. This workshop will be cosponsored by the Cancer Center Support Grant (CCSG, CA 15704) and is described in more detail under 'New Initiatives"""""""".

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Sorror, Mohamed L; Gooley, Ted A; Maclean, Kirsteen H et al. (2018) Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. Bone Marrow Transplant :
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Correnti, Colin E; Laszlo, George S; de van der Schueren, Willem J et al. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:1239-1243
Roesch, Ferdinand; OhAinle, Molly; Emerman, Michael (2018) A CRISPR screen for factors regulating SAMHD1 degradation identifies IFITMs as potent inhibitors of lentiviral particle delivery. Retrovirology 15:26
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020
Burwick, Nicholas; Zhang, Michael Y; de la Puente, Pilar et al. (2017) The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res 55:23-32
Venkataraman, G M; Kennedy, L J; Little, M-T E et al. (2017) Thirteen novel canine dog leukocyte antigen-88 alleles identified by sequence-based typing. HLA 90:165-170

Showing the most recent 10 out of 267 publications